Narrative review / 2020
Omega-3 fatty acids produce variable cardiovascular effects depending on their specific formulation and dosage.
This review summarizes findings from contemporary clinical trials investigating the cardioprotective effects of omega-3 fatty acids, specifically EPA and DHA. While early trials showed cardiovascular benefits with fish oils, subsequent studies largely failed to replicate these results. Recent trials have shown cardiovascular risk reduction with high-dose EPA, but not with lower doses or a carboxylic acid formulation combining EPA and DHA.
- Study type
- Narrative review of clinical trials
- Who was studied
- Participants in contemporary clinical trials of omega-3 fatty acids
- What was measured
- Cardiovascular outcomes and risk reduction
THE PAPER
The fish-oil paradox.
Nicholls SJ, Nelson AJ. Curr Opin Lipidol, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.